Starling Oncology
STLN
34 hedge funds and large institutions have $6.98M invested in Starling Oncology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 6 closing their positions.
250% more capital inflows, than outflows
Capital inflows: $2.05M | Capital outflows: $585K
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
2.15% more ownership
Funds ownership: 25.12% → 27.27% (+2.2%)
13% less funds holding
Funds holding: 39 → 34 (-5)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cincinnati Insurance
Fairfield,
Ohio
|
+$553K |
| 2 |
TIFF Advisory Services
Radnor,
Pennsylvania
|
+$503K |
| 3 |
Quattro Financial Advisors
The Woodlands,
Texas
|
+$44.2K |
| 4 |
Bank of New York Mellon
New York
|
+$33.2K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$73.9K |
| 2 |
Renaissance Technologies
New York
|
-$70.2K |
| 3 |
Millennium Management
New York
|
-$50.2K |
| 4 |
Vanguard Personalized Indexing Management
Oakland,
California
|
-$8.27K |
| 5 |
Jane Street
New York
|
-$5.68K |
STLN Hedge Fund Activity: Q3 2024 in Review
34 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q3 2024, worth a combined $6.98M — down 21% from $8.83M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of STLN and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 13 added.
The largest buyer was Cincinnati Insurance, adding an estimated $553K. The largest seller was Citadel Advisors, cutting an estimated $73.9K.
- 34 institutional investors held Starling Oncology (STLN) as of Q3 2024, down from 39 in Q2 2024.
- Funds reported $6.98M of Starling Oncology stock for Q3 2024, down 21% quarter-over-quarter.
- 2 funds opened new Starling Oncology positions in Q3 2024 and 6 closed out, a net change of -4 holders.
- The largest Starling Oncology buyer in Q3 2024 was Cincinnati Insurance, an estimated $553K added.
- The largest Starling Oncology seller in Q3 2024 was Citadel Advisors, an estimated $73.9K sold.
Based on aggregated 13F filings for Q3 2024.